Key statistics
On Thursday, Kazia Therapeutics Ltd (KZIA:NAQ) closed at 8.70, 204.20% above the 52 week low of 2.86 set on Apr 17, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 8.75 |
|---|---|
| High | 9.09 |
| Low | 8.55 |
| Bid | 8.50 |
| Offer | 8.90 |
| Previous close | 8.78 |
| Average volume | 236.19k |
|---|---|
| Shares outstanding | 107.32k |
| Free float | 102.36k |
| P/E (TTM) | -- |
| Market cap | 94.23m USD |
| EPS (TTM) | -12.28 USD |
Data delayed at least 15 minutes, as of Mar 05 2026 20:49 GMT.
More ▼
- Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
- Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
- Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
- Kazia Therapeutics Regains Full Nasdaq Listing Compliance
- Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
More ▼
